Get the Stockscreener App
1.62
1.25%
0.02
Pre-market:
1.62
Inflarx Nv stock is traded at $1.62, with a volume of 974.43K.
It is up +1.25% in the last 24 hours and down -34.41% over the past month.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$1.60
Open:
$1.6
24h Volume:
974.43K
Relative Volume:
0.58
Market Cap:
$238.61M
Revenue:
$72,500
Net Income/Loss:
$-45.96M
P/E Ratio:
-2.3775
EPS:
-0.6814
Net Cash Flow:
$-44.56M
1W Performance:
-5.26%
1M Performance:
-34.41%
6M Performance:
+62.00%
1Y Performance:
+106.63%
1-Day Range:
$1.55
$1.6681
1-Week Range:
$1.55
$1.76
52-Week Range:
$0.7406
$2.9489
Inflarx Nv Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx Nv
|
1.62 | 238.61M | 72,500 | -45.96M | -44.56M | -0.6814 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inflarx Nv Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-02-25 | Resumed | H.C. Wainwright | Buy |
| May-29-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx Nv Stock (IFRX) Latest News
InflaRx N.V. Q1 2026 Earnings: Narrower-than-Expected Loss Despite Stock DeclineEarnings Growth Forecast - newsline.com
IFRX Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical Progress; Stock SlipsPost-Announcement Reaction - newsline.com
What Do Analysts Say About InflaRx N.V. (IFRX)? - Insider Monkey
IFRX Q4 2025 Earnings: Narrower-than-Expected Loss Fails to Stem Stock DeclinePre-Earnings Drift - newsline.com
InflaRx prices $150 million share offering at $2 per share - Investing.com
InflaRx to develop izicopan for kidney disease treatment - Investing.com
InflaRx prices $150 million share offering at $2 per share By Investing.com - Investing.com Australia
INFLARX NV (IFRX) Stock Chart - ChartMill
InflaRx stock surges on AAV drug development plan - Investing.com
InflaRx investor update: Izicopan set to take center stage in AAV and renal disease pipeline - MSN
InflaRx NV stock (NL0012661870): Nasdaq-listed biotech trades lower ahead of next earnings update - AD HOC NEWS
Raymond James Upgrades InflaRx Following Clinical Shift - asatunews.co.id
Wall Street Firms Upgrade InflaRx Following Strategic Kidney Disease Focus - HarianBasis.co
InflaRx N.V. (IFRX) Edges Higher with Modest Gains, Tests Key Resistance ZoneHigh Volume Stocks - The Legal Advocate
Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now - Yahoo Finance
5 Most Volatile Penny Stocks to Buy Now - Insider Monkey
InflaRx N.V. Shows Resilience: IFRX Stock Edges Higher on Modest VolumePassive Flow - newsline.com
InflaRx N.V. (IFRX) Tumbles 7% as Shares Test Key Support LevelsSmart Beta Flow - newsline.com
InflaRx (IFRX) Surges Nearly 5%, Testing Key Resistance at $2.88Last Point Support - thelegaladvocate.com
IFRX - Finviz
InflaRx (IFRX) Q4 2025 Earnings: Slight EPS Beat Amid Pre‑Revenue PhaseStrong Earnings Momentum - The Legal Advocate
InflaRx N.V. (IFRX) Q4 2025 Earnings: Narrower Loss and Pipeline Progress Lift Sentiment - thelegaladvocate.com
InflaRx N.V. (IFRX) Surges 7.5% as Shares Test Key Resistance LevelWave Equality - The Legal Advocate
Long term debt to total assets ratio of InflaRx N.V. – HAM:IF0 - TradingView
Discontinued operations of InflaRx N.V. – HAM:IF0 - TradingView
EBIT per share of InflaRx N.V. – HAM:IF0 - TradingView
EBITDA per share of InflaRx N.V. – HAM:IF0 - TradingView
EBITDA of InflaRx N.V. – HAM:IF0 - TradingView
InflaRx N.V. Cash Flow – HAM:IF0 - TradingView
InflaRx N.V. Balance Sheet – HAM:IF0 - TradingView
InflaRx N.V. Statistics – HAM:IF0 - TradingView
Non-controlling/minority interest of InflaRx N.V. – HAM:IF0 - TradingView
InflaRx N.V. (IFRX) Stock Analysis: +2.11% Gain — What to Watch 2026-05-20Zigzag Correction - newsline.com
InflaRx NV stock (NL0012661870): what’s behind the latest trading volatility after Gohibic’s slo - AD HOC NEWS
InflaRx regains Nasdaq compliance after shares trade above $1 - MSN
InflaRx to develop izicopan for kidney disease treatment By Investing.com - Investing.com Nigeria
InflaRx N.V. (IFRX) Up +1.26% — Is There More Room to Run? 2026-05-18Upthrust Pattern - newsline.com
InflaRx NV stock (NL0012661870): May data from a recent YTD ranking - AD HOC NEWS
InflaRx NV (IFRX) price target decreased by 17.33% to 9.03 - MSN
Farallon funds and managers report shared stakes in InflaRx (IFRX) - Stock Titan
InflaRx NV (IFRX) price target decreased by 16.67% to 7.29 - MSN
Raymond James upgrades InflaRx NV (IFRX) - MSN
Inflarx stock upgraded to Strong Buy at Raymond James on drug potential - Investing.com UK
Inflarx stock upgraded to Strong Buy at Raymond James on drug potential By Investing.com - Investing.com South Africa
InflaRx NV Stock (IFRX): Favorable Izicopan Data Released - AD HOC NEWS
TradingKey - TradingKey
Inflarx Nv Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):